John Bartlett

Overview

Dr. John Bartlett is pursuing an integrated platform of research focused on the development of novel cancer diagnostics.

In 2011, Dr. Bartlett became director of OICR’s Transformative Pathology Program and the Ontario Tumour Bank. He is developing new diagnostic approaches to improve patient diagnosis and treatment. By gaining an understanding of the molecular complexity of cancer, accurate diagnostic approaches can be developed to ensure that patients receive the most appropriate treatment. Novel diagnostic tools are required to accurately identify molecular sub-types of cancer and to predict the effectiveness of treatment. Dr. Bartlett has contributed to the development of translational research within multi-centre clinical trials, several of which have led to new insights into selecting appropriate therapeutics for breast cancer patients. He aims to foster research in other laboratories across the province to accelerate the discovery of novel diagnostics for cancer.

Contact Information

Mrs. Olga Serebrennik

olga [dot] serebrennikatoicr [dot] on [dot] ca

Telephone: 647-259-4241

Affiliations

2011 - Program Director, Transformative Pathology, Ontario Institute for Cancer Research (OICR).
2011 - Honorary Professor, College of Medicine and Veterinary Medicine, University of Edinburgh.
2008 - 2011Professor of Molecular Pathology, College of Medicine and Veterinary Medicine, University of Edinburgh.
2006 - 2008Reader in Molecular Pathology, University of Edinburgh.
2004 - 2006Reader , University Department Surgery, Glasgow Royal Infirmary.
1998 - 2004Senior Lecturer, University Department of Surgery, Glasgow Royal Infirmary.
1992 - 1997Lecturer, University Department of Surgery, Glasgow Royal Infirmary.

Research Output

  • Pritchard KI, Munro A, O'Malley FP, Tu D, Li X, Levine MN, Shepherd L, Chia S, Bartlett JM.
    Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial.
    • Breast Cancer Res Treat Jan 2012;131(2):541-51.
  • Spears M, Cunningham CA, Taylor KJ, Mallon EA, Thomas JS, Kerr GR, Jack WJ, Kunkler IH, Cameron DA, Chetty U, Bartlett JM.
    Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progression.
    • J Pathol Aug 2012;227(4):481-9
  • Bartlett JMS, Bloom KJ, Piper T, Lawton TJ, van de Velde CJH, Ross DT, Seitz RS, Beck RA, Hasenburg A, Kieback D, Putter H, Markopoulos C, Dirix L, Seynaeve C, Rea D.
    Mammostrat as an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in the TEAM Pathology Study.
    • J Clin Oncol Dec 2012;30(36):4477-84
  • Polley MYC, Leung SCY, McShane LM, Gao D, Hugh JC, Mastropasqua MG, Viale G, Zabaglo LA, Penault-Llorca F, Bartlett JMS, Gown AM, Symmans WF, Piper T, Mehl E, Enos RA, Hayes DF, Dowsett M, Nielsen TO, on behalf of the International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Cooperative Group members
    An International Ki67 Reproducibility Study.
    • Journal of the National Cancer Institute (Accepted pending revisions – May 2013)
  • Bartlett JMS, Brookes CL, Piper T, van de Velde CJH, Stocken D, Lyttle N, Hasenburg A, Quintayo MA, Kieback DG, Putter H, Markopoulos C, Meershoek-Klein Kranenbarg E, Mallon EA, Dirix LY, Seynaeve C, Rea DW.
    Do Type 1 receptor tyrosine kinases inform treatment choice?: a prospectively planned analysis of the TEAM trial.
    • British Journal of Cancer (in press Sept. 2013)